This page lists members of our management team who are responsible for delivering on our mission of providing breakthrough scientific software solutions and services that empower our users to achieve their goals of improving human health and quality of life.
Ramy Farid, Ph.D.
Ramy Farid, President, joined Schrödinger in 2002. He received his Ph.D. in Chemistry from Caltech in 1991, and was an NIH Postdoctoral Fellow at the University of Pennsylvania. He was an Assistant Professor at Rutgers University prior to joining Schrödinger. His research at Rutgers focused on computational protein design, which resulted in a number of high-profile publications. After joining Schrödinger, Ramy rapidly rose through a series of leadership positions as well as led many research and development projects; he also authored several highly-cited publications applying computational tools to drug discovery.
Murco Ringnalda, Ph.D.
– Chief Financial Officer
Murco Ringnalda, Chief Financial Officer, is a co-founder of Schrödinger, and was the first employee. He received his Ph.D. in Chemical Physics from the University of Texas at Austin in 1990. He was also a Research Fellow at Caltech prior to joining Schrödinger. He holds an M.B.A. from the University of Oregon and a B.A. from Reed College.
Mark Murcko, Ph.D.
– Senior Vice President, Strategy
Mark Murcko, Senior Vice President of Strategy, joined Schrödinger in 2012 after being an advisor and consultant for Schrödinger since 2008. Prior to joining Schrödinger, he was Vice President, Chief Technology Officer and Chair of the Scientific Advisory Board of Vertex Pharmaceuticals. Dr. Murcko is a co-inventor of Incivek™ (telaprevir), the world's most widely prescribed HCV protease inhibitor, as well as Agenerase™ (amprenavir) and Lexiva™ (fosamprenavir), Vertex's two marketed drugs for HIV. He is also a co-inventor of 8 other clinical candidates in the areas of cancer, inflammation/immunology, and infectious disease and was responsible for starting many of Vertex's programs in these and other disease areas. Prior to Vertex, Dr. Murcko worked at Merck Sharpe & Dohme, where he helped discover clinical candidates against cardiovascular and ocular diseases, including inhibitors of the enzyme carbonic anhydrase for the treatment of glaucoma. One of Merck's development candidates in this area, Trusopt™ (dorzolamide), became the first marketed drug in pharmaceutical history to result from a structure-based drug design program. Dr. Murcko is highly regarded as an innovator and champion of disruptive technologies. He has served on the editorial boards of many scientific publications, including the Journal of Medicinal Chemistry and Drug Discovery Today, and will serve as the Chair of the 2013 Gordon Research Conference in Medicinal Chemistry. He is a co-inventor on more than 40 issued patents and has co-authored more than 85 scientific articles.
Dr. Jörg Weiser
– Senior Vice President & Managing Director
Jörg Weiser, Senior Vice President and Managing Director, Schrödinger GmbH, joined in 2002. He received his doctorate in Organic Chemistry from the Georg-August-University in Göttingen, Germany in 1996. He conducted post-doctoral research at Columbia University in New York from 1997 to 1999 and worked in the MacroModel team of Prof. Clark Still. He was co-founder and Managing Director of Anterio, a German consulting and research company established in 1999, prior to joining Schrödinger.
– Senior Vice President, Business Development
Cony D’Cruz, Senior Vice President of Business Development, was previously President of Proteros US, Inc. and Chief Business Officer at Proteros responsible for all commercial activities. Prior to Proteros Cony was Senior Vice President, Business Development, North America for Evotec AG Hamburg for over nine years and was responsible for managing all commercial activities of Evotec in North America. In these commercial roles he initiated innovative discovery deal structures with venture companies, research foundations and large integrated deals with pharmaceutical companies. Prior to Evotec, Cony worked at IGEN, Inc. where he was responsible for the marketing strategy of the life sciences division; in addition, he was involved in investor presentations and fund raising. Prior to IGEN Cony worked for Corning Inc. in the US and in Europe for twelve years. At Corning, he held a number of sales and marketing roles with increasing responsibility. In his last position Cony was responsible for marketing at a new business unit focused on high-throughput screening and molecular biology products. Cony received a BSc. in Applied Biology from the University of London and an MBA from The Open University, Milton Keynes UK.
Shi-Yi Liu, Ph.D.
– Senior Vice President, Marketing
Shi-Yi Liu, Senior Vice President of Marketing, joined Schrödinger in 1997. She received her Ph.D. in Physical Chemistry from the University of Illinois in 1987. She worked at Allied-Signal as a computational chemist before becoming a founding member of the CAChe Group. In her position as Principal Chemist, she authored the molecular mechanics and molecular dynamics programs of CAChe Scientific. She holds an M.B.A. from the University of Oregon and a B.S. in Chemistry from the University of Washington.
– Vice President & General Counsel
Yvonne Tran, Vice President and General Counsel, joined Schrödinger in 2010. Prior to joining Schrödinger, she served as Senior Corporate Counsel at Oracle America, Inc. and as Deputy General Counsel at DoubleClick Inc. As an in-house lawyer, she negotiated complex intellectual property and commercial transactions and provided legal support on M&A matters and intellectual property litigations. Yvonne worked at various law firms in New York immediately after law school, and her practice included intellectual property counseling and litigation. She has extensive experience in the software and technology services industries. Yvonne graduated from Yale in 1992 with a B.A. in Molecular Biophysics & Biochemistry and from the University of Virginia School of Law in 1995.
Michelle Byington, Ph.D.
– Vice President, Human Resources
Michelle Byington, Vice President of Human Resources, joined Schrödinger in 2008. Her career has focused on recruiting candidates to work in the life sciences since completing her Ph.D. in Clinical Psychology from Columbia University in 2001. She completed her undergraduate work in Psychology at Yale University in 1994.
– Vice President, North America Sales
John Dowling, Vice President of North America Sales, joined Schrödinger in 2003. John previously worked in Sales at Lion Bioscience, Accelrys, Silicon Graphics Inc., and Computervision. He received his BSME from Massachusetts Maritime Academy in 1978, and his ALM Masters in Biology from Harvard University in 1998 working with Harvard Professor and 1980 Nobel Laureate Walter Gilbert.
– Vice President, Japan Operations
Shunichi Ozawa, Vice President of Japan Operations, joined Schrödinger in 2011, and is Schrödinger KK's 代表取締役社長. Mr. Ozawais responsible for managing all of Schrödinger's operations in Japan. Prior to that, he was the lead salesperson of Schrödinger products for Infocom Corporation, Schrödinger's former exclusive distributor in Japan since 1997. Mr. Ozawa received a Bachelor of Science degree in Industrial Chemistry from Meiji University in 1996.
Leah Frye, Ph.D.
– Vice President, Drug Discovery Applications Group
Leah Frye, Vice President of the Drug Discovery Applications Group, joined Schrödinger in 2001. She received her Ph.D. in Synthetic Organic Chemistry from The Johns Hopkins University in 1984, and was an NIH NRSA Postdoctoral Fellow in the Department of Pharmacology and Experimental Therapeutics at The Johns Hopkins School of Medicine. Before joining Schrödinger, Leah was a Principal Scientist at Boehringer Ingelheim Pharmaceuticals and prior to that she was an Associate Professor of Chemistry at Rensselaer Polytechnic Institute.
Woody Sherman, Ph.D.
– Vice President, Applications Science
Woody Sherman, Vice President of Applications Science, joined Schrödinger in 2004. He received his Ph.D. from MIT where he developed a novel method for optimizing ligand binding specificity across a panel of targets. While in graduate school he completed an internship at Biogen where he helped develop novel methods to enhance antibody affinity that resulted in a patent and publication. He has authored papers on induced-fit docking, binding specificity, antibody design, fragment docking, and hybrid ligand/structure-based methods. He is also co-author on two patents. Woody is a reviewer for many top journals related to computational chemistry and drug design and is on the Editorial Board of Chemical Biology & Drug Design as well as The Journal of Chemical Information and Modeling.
Volker Eyrich, Ph.D.
– Vice President, Professional Solutions
Volker Eyrich, Vice President of Professional Solutions, joined Schrödinger in 2001. He received his Ph.D. in Physical Chemistry from Columbia University in 2000. In his graduate and post-doctoral research, he focused on the development of novel algorithms for ab initio protein folding simulations as well as large-scale benchmarking of protein structure prediction servers.
– Vice President, Enterprise Products
Scott Becker, Vice President of Enterprise Products, joined Schrödinger in 2012. He received his BS in Computational Biology from University of Pennsylvania. Scott is a technical entrepreneur, startup advisor, and angel investor. He was Co-Founder and CTO of Invite Media, a venture backed advertising startup that was acquired by Google in 2010.
Robert Abel, Ph.D.
– Vice President, Scientific Development
Robert Abel, Vice President of Scientific Development, is responsible for leading efforts to further improve induced-fit docking, free energy perturbation theory, physics-based affinity scoring, and protein structure prediction; as well as supervising the Schrödinger R&D portfolio. Robert obtained his PhD from Columbia University for his work with Professor Richard Friesner on methods to quantify the role of the solvent in protein-ligand binding. He has also been awarded NSF and DHS research fellowships; published on a variety of topics including protein-ligand binding, protein dynamics, protein structure prediction, energy function development, and fluid thermodynamics; served as a referee for several prestigious journals; and coauthored multiple patent applications. Since joining Schrödinger in 2009, Robert has advanced though a number of roles to his current position.
Mathew D. Halls, Ph.D.
– Executive Director, Materials Science
Mathew D. Halls, Executive Director of Materials Science, is responsible for leading the materials science program at Schrödinger. Prior to joining Schrödinger in 2012, he was a senior scientist and account manager at Materials Design, Inc. and Accelrys, Inc. Before that he held the prestigious E.R. Davidson Fellowship in theoretical chemistry at Indiana University and earlier was the Manager of the Scientific Simulation and Modeling Group at Zyvex Corporation. Mat has worked with Fortune 500 companies to advance the adoption of atomic-scale materials modeling techniques in diverse industries including aerospace, electronics and specialty chemicals. He has made significant research contributions in areas such as computational spectroscopy, organic optoelectronic materials, nanocarbon-polymer interfaces, thin-film precursors and deposition processes and battery electrolyte additives; with his work being cited more than 2000 times.